Center for Health Services Research in Primary Care, Durham Veteran Affairs Medical Center (152), 508 Fulton St, Durham, NC 27705
J Clin Psychiatry. 2014 May;75(5):e424-40. doi: 10.4088/JCP.13r08558.
Individuals with serious mental illness have high rates of cardiovascular disease (CVD) risk factors and mortality. This systematic review was conducted to evaluate pharmacologic and behavioral interventions to reduce CVD risk in adults with serious mental illness.
MEDLINE, EMBASE, PsycINFO, ClinicalTrials.gov, and Cochrane Database of Systematic Reviews were searched from January 1980 to July 2012 for English language studies. Examples of search terms used include schizophrenia, bipolar disorder, antipsychotics, weight, glucose, lipid, and cardiovascular disease.
Two reviewers independently screened citations and identified 33 randomized controlled trials of at least 2 months' duration that enrolled adults with serious mental illness and evaluated pharmacologic or behavioral interventions targeting weight, glucose, or lipid control.
Reviewers extracted data, assessed applicability, and evaluated study quality; the team jointly graded overall strength of evidence.
We included 33 studies. Most studies targeted weight control (28 studies). Compared with control groups, weight control was improved with behavioral interventions (mean difference = -3.13 kg; 95% CI, -4.21 to -2.05), metformin (mean difference = -4.13 kg; 95% CI, -6.58 to -1.68), anticonvulsive medications topiramate and zonisamide (mean difference = -5.11 kg; 95% CI, -9.48 to -0.74), and adjunctive or antipsychotic switching to aripiprazole (meta-analysis not possible). Evidence was insufficient for all other interventions and for effects on glucose and lipid control. The small number of studies precluded analyses of variability in treatment effects by patient characteristics.
Few studies have evaluated interventions addressing 1 or more CVD risk factors in people with serious mental illness. Glucose- and lipid-related results were mainly reported as secondary outcome assessments in studies of weight-management interventions. Comparative effectiveness studies are needed to test multimodal strategies, agents known to be effective in nonserious mental illness populations, and antipsychotic-management strategies.
患有严重精神疾病的个体患心血管疾病(CVD)风险因素和死亡率较高。本系统评价旨在评估药物和行为干预措施,以降低患有严重精神疾病的成年人的 CVD 风险。
从 1980 年 1 月至 2012 年 7 月,MEDLINE、EMBASE、PsycINFO、ClinicalTrials.gov 和 Cochrane 系统评价数据库搜索英文研究。使用的搜索词示例包括精神分裂症、双相情感障碍、抗精神病药物、体重、葡萄糖、脂质和心血管疾病。
两名评审员独立筛选引用文献并确定了 33 项至少持续 2 个月的随机对照试验,这些试验招募了患有严重精神疾病的成年人,并评估了针对体重、葡萄糖或脂质控制的药物和行为干预措施。
评审员提取数据、评估适用性并评估研究质量;团队共同对整体证据强度进行分级。
我们纳入了 33 项研究。大多数研究针对体重控制(28 项研究)。与对照组相比,行为干预可改善体重控制(平均差异=-3.13kg;95%CI,-4.21 至-2.05)、二甲双胍(平均差异=-4.13kg;95%CI,-6.58 至-1.68)、抗惊厥药物托吡酯和佐米曲坦(平均差异=-5.11kg;95%CI,-9.48 至-0.74)和增效或抗精神病药物换用阿立哌唑(无法进行荟萃分析)。其他干预措施和对血糖和血脂控制的影响证据不足。研究数量较少,无法按患者特征分析治疗效果的变异性。
很少有研究评估针对严重精神疾病患者 1 种或多种 CVD 风险因素的干预措施。葡萄糖和脂质相关结果主要作为体重管理干预研究的次要结果报告。需要进行比较有效性研究,以测试多模式策略、在非严重精神疾病人群中已知有效的药物以及抗精神病药物管理策略。